Become a Friend Donate
PETBioNewsCommentPodcast: Risk Management - Breast Cancer, Business and Patents

BioNews

Podcast: Risk Management - Breast Cancer, Business and Patents

Published 30 June 2014 posted in Comment and appears in BioNews 760

Author

James Brooks

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Does the pharmaceutical and biotech industry's profit motive actually pervert rather than inspire innovation and the hunt for new therapies? Is the patent system well suited to a new life sciences landscape including stem cell and gene therapies?...

Does the pharmaceutical and biotech industry's profit motive actually pervert rather than inspire innovation and the hunt for new therapies? Is the patent system well suited to a new life sciences landscape including stem cell and gene therapies?

What will be the impact of the famous Myriad case, where the US Supreme Court effectively ruled against companies patenting gene sequences as they occur in nature? And, focusing on breast cancer, is Angelina Jolie's assertion that 'the cost of testing for BRCA1 and BRCA2...remains an obstacle for many women' justified?

This podcast features interviews on those questions with the four people - two intellectual property (IP) specialists, an expert in genetics and insurance and a former patient - who spoke at the Progress Educational Trust (PET)'s event 'Risk Management: Breast Cancer, Business and Patents', part of the Wellcome Trust-supported project 'Breast Cancer: Chances, Choices and Genetics'.

Listen to the podcast using the player below.

00:00 James Brooks: Introduction
02:15 Jenny Dunlop: Commercialisation of breast cancer, the pharma industry and care.data
06:00 Dr Ian Cox: Genetics and insurance
09:10 Dr Angela Kukula: IP; the Myriad case; academia/ industry partnerships
13:40 Alexander Denoon: IP and mechanisms to reward innovation in life sciences

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 June 2015 • 3 minutes read

Cancer patient appeals gene patenting decision

by Paul Waldron

Australia's highest court will decide whether isolated molecules of DNA linked to a gene mutation associated with an increased risk of hereditary breast and ovarian cancers are patentable under Australian law....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 July 2014 • 3 minutes read

Canada: Call to halt use of gene test results in insurance calculations

by Rebecca Carr

Canada's Office of the Privacy Commissioner has issued a statement urging the life and health insurance industry to refrain from asking applicants for access to existing genetic test results...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
7 July 2014 • 4 minutes read

Breast Cancer Risk: Facts, Fictions and the Future

by Dr Nikki Davis

The Progress Educational Trust's enlightening series of events on breast cancer came to a close on Thursday with 'Breast cancer risk: Facts, fiction and the future'....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
9 June 2014 • 5 minutes read

Risk Management: Breast Cancer, Business and Patents

by Simon Hazelwood-Smith

The backdrop to the third event in the Progress Educational Trust's 'Breast Cancer: Chances, Choices and Genetics' series was the Myriad Genetics gene patenting legal saga, which came to a conclusion last year with Myriad being denied a patent on the isolated forms of the BRCA genes...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
2 June 2014 • 2 minutes read

Podcast: Risk Assessment - Breast Cancer, Prediction and Screening

by James Brooks

Is the benefit attributed to widespread breast cancer screening programmes supported by the evidence? What to make of the phenomenon of overdiagnosis, where patients are treated for cancers that would not have spread or been problematic in their lifetime?...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
12 May 2014 • 5 minutes read

Risk Assessment: Breast Cancer, Prediction and Screening

by Dr Jamie Heather

Doctors, survivors and supporters again converged in a basement lecture theatre in Bloomsbury for the second event in PET's 'Breast Cancer' series. On the cards this night: prediction and screening...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
28 April 2014 • 2 minutes read

Podcast: Relative Risk - Breast Cancer and Genetics

by James Brooks

Did Angelina Jolie's famous editorial in the New York Times a year ago inspire an overemphasis on genetic risk in breast cancer? Or has it saved lives by bringing the issue out into the open?...

Leave a Reply

«